Aigen Investment Management’s Charles River Laboratories CRL Stock Holding History

Aigen Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,536	Closed	-$231K	–	839
2025 Q1	$231K	Buy	+1,536	New	+$258K	0.04%	589
2024 Q3	–	Sell	-1,445	Closed	-$299K	–	780
2024 Q2	$299K	Buy	+1,445	New	+$327K	0.06%	470
2022 Q2	–	Sell	-4,011	Closed	-$1.14M	–	564
2022 Q1	$1.14M	Buy	4,011 +1,987	+98%	+$613K	0.2%	140
2021 Q4	$733K	Buy	+2,024	New	+$786K	0.05%	507
2020 Q2	–	Sell	-137	Closed	-$17K	–	905
2020 Q1	$17K	Buy	+137	New	+$20.5K	﹤0.01%	1103

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Aigen Investment Management's CRL Position: Q2 2025 in Review

Aigen Investment Management sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 1,536 shares — an estimated $231K sold.

Aigen Investment Management first reported a position in CRL in Q1 2020 and held it in 5 quarters. The position peaked at $1.14M in Q1 2022. 518 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

Aigen Investment Management reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
Aigen Investment Management sold 1,536 Charles River Laboratories shares in Q2 2025, an estimated $231K.
Aigen Investment Management first reported a position in Charles River Laboratories in Q1 2020 and held it in 5 quarters.
Aigen Investment Management's Charles River Laboratories position peaked at $1.14M in Q1 2022.
518 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Aigen Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.